Mahmoudjafari Z, Di Maio D, Li J, Rosettie KL, et al. Glofitamab results in cost savings versus epcoritamab in relapsed/refractory diffuse large B-cell lymphoma: a total cost of care analysis(double dagger). Leuk Lymphoma 2025 Apr 9:1-8. doi: 10.1080/10428194.2025.2486437.
PMID: 40202060